Società | Nome | Borsa | Settore | Industria | Capitalizzazione di mercato | Rapporto Prezzo/Utile | Rapporto PEG | Ultimo prezzo di scambio | Variazione giornaliera (%) | Fair Value | Rialzo Fair Value | Etichetta Fair Value | Price Target (analisti) | Rialzo target analisti | Salute complessiva |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly | NYSE | Salute | Prodotti farmaceutici | 826,59 Mrd USD | 112,7x | 8,72 | 917,97 USD | 0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 13,1% Rialzo | Fai l’upgrade a Pro+ | |
UnitedHealth | NYSE | Salute | Fornitori e servizi sanitari | 525,89 Mrd USD | 36,6x | -1,21 | 569,61 USD | 0,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 9,1% Rialzo | Fai l’upgrade a Pro+ | |
Novo Nordisk ADR | NYSE | Salute | Prodotti farmaceutici | 521,60 Mrd USD | 40x | 1,16 | 118,09 USD | -0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 28,8% Rialzo | Fai l’upgrade a Pro+ | |
J&J | NYSE | Salute | Prodotti farmaceutici | 397,44 Mrd USD | 27x | 0,11 | 165,12 USD | 0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 5,6% Rialzo | Fai l’upgrade a Pro+ | |
AbbVie | NYSE | Salute | Prodotti farmaceutici | 333,10 Mrd USD | 62,8x | -1,68 | 188,86 USD | 0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 6,9% Rialzo | Fai l’upgrade a Pro+ | |
Merck&Co | NYSE | Salute | Prodotti farmaceutici | 275,69 Mrd USD | 20,1x | 0,06 | 108,70 USD | -1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 24,8% Rialzo | Fai l’upgrade a Pro+ | |
Roche Holding Participation | OTC Markets | Salute | Prodotti farmaceutici | 275,54 Mrd USD | 22,5x | -6,26 | 312,62 USD | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Roche Holding ADR | OTC Markets | Salute | Prodotti farmaceutici | 275,54 Mrd USD | 22,5x | -6,26 | 39,56 USD | 1,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 21,3% Rialzo | Fai l’upgrade a Pro+ | |
AstraZeneca ADR | NASDAQ | Salute | Prodotti farmaceutici | 241,28 Mrd USD | 37,4x | 8,67 | 78,26 USD | 0,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 16,6% Rialzo | Fai l’upgrade a Pro+ | |
AstraZeneca PLC | OTC Markets | Salute | Prodotti farmaceutici | 241,28 Mrd USD | 37,4x | 8,67 | 157,88 USD | 2,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Novartis ADR | NYSE | Salute | Prodotti farmaceutici | 236,46 Mrd USD | 14,8x | 0,2 | 117,18 USD | 0,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 3% Rialzo | Fai l’upgrade a Pro+ | |
Novartis | OTC Markets | Salute | Prodotti farmaceutici | 236,46 Mrd USD | 14,8x | 0,2 | 110,78 USD | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -25,1% Ribasso | Fai l’upgrade a Pro+ | |
Thermo Fisher Scientific | NYSE | Salute | Attrezzature e forniture medicali | 229,84 Mrd USD | 37,2x | 3,6 | 601,71 USD | 0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 10,7% Rialzo | Fai l’upgrade a Pro+ | |
Abbott Labs | NYSE | Salute | Attrezzature e forniture medicali | 205,12 Mrd USD | 36,1x | 4,38 | 119,39 USD | 1,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 10,3% Rialzo | Fai l’upgrade a Pro+ | |
Danaher | NYSE | Salute | Attrezzature e forniture medicali | 197,93 Mrd USD | 48,2x | -1,42 | 274,38 USD | 0,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 6,3% Rialzo | Fai l’upgrade a Pro+ | |
Intuitive Surgical | NASDAQ | Salute | Attrezzature e forniture medicali | 185,56 Mrd USD | 87,9x | 1,79 | 521,10 USD | 10% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 6,8% Rialzo | Fai l’upgrade a Pro+ | |
Amgen | NASDAQ | Salute | Prodotti farmaceutici | 172,94 Mrd USD | 55,2x | -0,92 | 321,66 USD | 0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 4,3% Rialzo | Fai l’upgrade a Pro+ | |
Pfizer | NYSE | Salute | Prodotti farmaceutici | 165,47 Mrd USD | -63,7x | 0,57 | 29,22 USD | -0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 9,3% Rialzo | Fai l’upgrade a Pro+ | |
Stryker | NYSE | Salute | Attrezzature e forniture medicali | 140,69 Mrd USD | 40,8x | 1,47 | 369,56 USD | 2,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 5,8% Rialzo | Fai l’upgrade a Pro+ | |
Sanofi ADR | NASDAQ | Salute | Prodotti farmaceutici | 137,09 Mrd USD | 14,3x | -0,58 | 54,93 USD | 0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 16,7% Rialzo | Fai l’upgrade a Pro+ | |
Boston Scientific | NYSE | Salute | Attrezzature e forniture medicali | 129,90 Mrd USD | 70,7x | 0,67 | 88,07 USD | 1,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 4,1% Rialzo | Fai l’upgrade a Pro+ | |
Vertex | NASDAQ | Salute | Ricerca medica e biotecnologica | 124,74 Mrd USD | -254,6x | 2,21 | 483 USD | -3,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 3,9% Rialzo | Fai l’upgrade a Pro+ | |
Medtronic | NYSE | Salute | Attrezzature e forniture medicali | 118,21 Mrd USD | 30,9x | 3,05 | 92,24 USD | 2,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 6,9% Rialzo | Fai l’upgrade a Pro+ | |
Bristol-Myers Squibb | NYSE | Salute | Prodotti farmaceutici | 108 Mrd USD | -16,5x | 0,09 | 53,23 USD | 0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 2,5% Rialzo | Fai l’upgrade a Pro+ | |
Gilead | NASDAQ | Salute | Prodotti farmaceutici | 107,90 Mrd USD | 102,9x | -1,24 | 86,72 USD | -0,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -0,3% Ribasso | Fai l’upgrade a Pro+ | |
Regeneron Pharma | NASDAQ | Salute | Ricerca medica e biotecnologica | 107,40 Mrd USD | 24,7x | 990,68 USD | -0,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 21,2% Rialzo | Fai l’upgrade a Pro+ | ||
HCA | NYSE | Salute | Fornitori e servizi sanitari | 107,38 Mrd USD | 19,2x | 3,83 | 415,54 USD | 2,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -1,3% Ribasso | Fai l’upgrade a Pro+ | |
Essilor International SA | OTC Markets | Salute | Attrezzature e forniture medicali | 107,20 Mrd USD | 42,7x | -12,09 | 116,93 USD | 1,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 5,2% Rialzo | Fai l’upgrade a Pro+ | |
Elevance Health | NYSE | Salute | Fornitori e servizi sanitari | 99,48 Mrd USD | 15,6x | 2,08 | 430,77 USD | -3,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 36,1% Rialzo | Fai l’upgrade a Pro+ | |
CSL | OTC Markets | Salute | Prodotti farmaceutici | 97,64 Mrd USD | 36,7x | 1,8 | 101,12 USD | 0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 9,2% Rialzo | Fai l’upgrade a Pro+ |